The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

BACKGROUND: Current strategies to inhibit androgen receptor (AR) are circumvented in castration-resistant prostate cancer (CRPC). Cyclin-dependent kinase 7 (CDK7) promotes AR signalling, in addition to established roles in cell cycle and global transcription, providing a rationale for its therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Constantin, Theodora A., Varela-Carver, Anabel, Greenland, Kyle K., de Almeida, Gilberto Serrano, Olden, Ellen, Penfold, Lucy, Ang, Simon, Ormrod, Alice, Leach, Damien A., Lai, Chun-Fui, Ainscow, Edward K., Bahl, Ash K., Carling, David, Fuchter, Matthew J., Ali, Simak, Bevan, Charlotte L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241923/
https://www.ncbi.nlm.nih.gov/pubmed/37076563
http://dx.doi.org/10.1038/s41416-023-02252-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241923/
https://www.ncbi.nlm.nih.gov/pubmed/37076563
http://dx.doi.org/10.1038/s41416-023-02252-8

Ejemplares similares